ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 36

The Use of Three-Dimensionally Printed β-Tricalcium Phosphate/Hydroxyapatite to Further Understand the Regulation of Adenosine Receptors in Osteoclast Formation and Promotion in Bone Regeneration

Stephanie Ishack1, Aranzazu Mediero1, John Ricci2 and Bruce N. Cronstein3, 1Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, 2Biomaterials, NYU Dental School, New York, NY, 3NYU School of Medicine, Division of Rheumatology, New York, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: 3D model, Adenosine receptors, bone remodeling, osteoblasts and therapeutic targeting

  • Tweet
  • Email
  • Print
Session Information

Title: Biology and Pathology of Bone and Joint: Osteoclasts, Osteoblasts and Bone Remodeling

Session Type: Abstract Submissions (ACR)

Background/Purpose Bone defects resulting from trauma or infection need timely and effective treatments to restore damaged bone. Using specialized three-dimensional (3-D) printing technology, combined with bioactive molecules, we can design custom 3-D scaffolds for bone repair. The Hydroxyapatite (HA)/Beta-Tri-Calcium Phosphate (B-TCP) scaffold components provide mechanical strength, conduct bone throughout the scaffold and remodel over time. Dipyridamole (DIPY) increases local adenosine levels by blocking cellular uptake of adenosine and stimulates bone regeneration. Because DIPY, adenosine and adenosine A2A receptor-specific agonists stimulate bone regeneration in mice as well as BMP-2, a growth factor currently used to promote bone regeneration, we tested the capacity of DIPY-coated matrices could promote successful bone regeneration

Methods 15% HA:85% B-TCP scaffolds were designed usingRobocad software, fabricated using a 3-D Robocasting system, and sintered at 1100°C for 4h. Scanning electron microscopy (SEM), micro-computed tomography (micro-CT), x-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR) and inductive coupled plasma (ICP) were used for material characterization. Vehicle, BMP-2 and DIPY drug scaffolds (scaffold + PBS, scaffold + DIPY or BMP-2, scaffold+ collagen + DIPY or BMP-2) were implanted in C57B6 (wild type, WT) and A2AKO mice with 3mm critical size defect for 2, 4 and 8 weeks. DIPY release from scaffold was assayed spectrophotometrically over time. MicroCT and histological analysis were conducted to determine the degree of new bone formation and remodeling.  

Results Quantitative and qualitative results from microCT showed similar and significant bone formation and remodeling in HA/B-TCP- DIPY and HA/B-TCP-BMP-2 scaffolds when compared to vehicle at 2, 4 and 8 weeks in WT mice (55% bone formation for in HA/B-TCP- DIPY and HA/B-TCP-BMP-2  vs 41% for vehicle,  N=5 per group; P≤ 0.01). Dipyridamole did not enhance bone formation in A2AKO mice 4 weeks after trephination (31% for HA/B-TCP- DIPY vs 27% for vehicle, N=5, p=ns). Histological analysis of WT mice showed increased bone formation and a trend toward increased remodeling in HA/B-TCP- DIPY and HA/B-TCP-BMP-2 scaffolds. Histologic examination of Dipyridamole treated scaffold in A2AKO mice showed no significant differences in bone formation when compare to vehicle treated scaffolds. Dipyridamole release from collagen coated scaffolds, maintain a constant concentration (10-6M) for up to 10 days.

Conclusion Dipyridanmole increases adenosine levels and targeting osteoblasts and osteoclasts via activation of the adenosine A2A receptor leads to increased bone regeneration in a murine model. Delivery of Dipyridamole in the 3-D ceramic scaffolds is a an effective approach for bone regeneration following orthopedic, dental and craniofacial procedures.


Disclosure:

S. Ishack,
None;

A. Mediero,
None;

J. Ricci,
None;

B. N. Cronstein,

Canfite Pharma,

1,

AstraZeneca,

2,

Cellgene,

2,

Gilead,

2,

NIH,

2,

NYU School of Medicine,

3,

Bristol-Myers Squibb,

5,

Pfizer Inc,

5,

Eli Lilly and Company,

5,

Rheumatology Reseach Foundation,

6,

ACR,

6,

Arthritis Foundation,

6.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-use-of-three-dimensionally-printed-%ce%b2-tricalcium-phosphatehydroxyapatite-to-further-understand-the-regulation-of-adenosine-receptors-in-osteoclast-formation-and-promotion-in-bone-regeneration/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology